摘要
目的探讨血浆氨基末端脑利钠肽前体（NT—proBNP）对判断慢性心力衰竭患者疗效及预后的价值。方法对研究组患者治疗前后及对照组血液中NT-proBNP检测结果、随访1年再住院率及病死率给予统计学分析。结果对照组健康人群NT—proBNP检测水平显著低于研究组治疗前，研究组治疗后血液中NT-proBNP检测水平显著低于治疗前；研究组血浆NT—proBNP较治疗前下降幅度不小于50％患者随访1年的再住院率和病死率为16．13％、3．23％，显著低于治疗前血浆NT—proBNP下降幅度小于50％患者的住院率和病死率（88．89％和66．67％，P〈0．05）。结论临床医生应根据血浆NT—proBNP检测结果诊断及治疗慢性心力衰竭疾病，治疗完成后根据NT—proBNP检测水平判断其预后效果并给予针对性的预防措施，降低再次住院率及病死率。
Objective To investigate the effect of NT-proBNP on patients with chronic heart failure and to determine the prognostic value. Methods The blood NF-proBNP results before treatment in study group and control group, rehospitalization rate and mortality rate of 1-year follow-up were analyzed. Results The level of NT-proBNP in control group was significantly lower than that of study group before treatment and the level of NT-proBNP in control group after treatment was also lower than that of before treatment. The 1 year readmission rate and mortality rate of patients whose NT-proBNP level decreased for less than 50% after treatment in comparision to pre treatment were 16. 13% and 3.23% respectively, which were significantly lower than those whose NT-proBNP level decreased for more than 50%, 88.89% and 66.67% （P 〈 0.05）. Conclusions Clinicians are suggested to diagnoze and treat patients with chronic heartdisease according to their NT-proBNP test results and thus provide targeted prevention measures to detect and reduce the rate of reospitalization and mortality.
出处
《中国实用医刊》
2015年第9期96-97,共2页
Chinese Journal of Practical Medicine
